Understanding ARIA: How Risky Are Leqembi and Kisunla? episode artwork

EPISODE · Aug 26, 2026 · 31 MIN

Understanding ARIA: How Risky Are Leqembi and Kisunla?

from Happy & Healthy with Amy · host Amy Lang

If your mom or dad has been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s, you may be weighing whether one of the newer treatments—Leqembi or Kisunla—could be worth considering.And then you hear the words brain swelling and bleeding.For a lot of families, that’s the moment the conversation stops.But here’s the problem: those words don’t tell you the whole story.The ARIA rates reported in Alzheimer’s drug trials can sound alarming when you hear them on their own. What they don’t tell you is what those cases actually looked like, how often symptoms occurred, why some people are at higher risk than others, or how doctors monitor for problems before they become more serious.That’s what we’re unpacking in Part 2 of this three-part series.In this episode, I’ll walk you through what ARIA—amyloid-related imaging abnormalities—actually means, why it happens, how it differs from an infusion reaction, and why the top-line percentages may not tell you nearly enough about your loved one’s individual risk.We’ll also look at an important question that doesn’t get enough attention:Why can two people taking the same Alzheimer’s drug have very different risk profiles?And there’s one more piece of the story that matters if you’re comparing Leqembi and Kisunla. The numbers from the original clinical trials are not necessarily the whole picture today.WHAT TO LISTEN FOR[00:00] Why hearing “brain swelling and bleeding” can make these treatments sound scarier than the full data suggests[05:05] How to tell the difference between an infusion reaction and something happening specifically in the brain[10:18] What the ARIA spectrum actually looks like—and why one percentage can hide very different outcomes[14:17] Why comparing the headline ARIA rates for Leqembi and Kisunla may lead you to the wrong conclusion[16:48] The blood-vessel condition that may help explain why ARIA happens in the first place[20:53] Why APOE4 status can dramatically change the risk conversation[20:53] What a baseline MRI can reveal before treatment even begins[20:53] Why blood thinners make the risk-benefit discussion more complicated[20:53] How ARIA can mimic a stroke—and why that matters in an emergency[25:57] Why anti-amyloid drugs are only one piece of a much bigger Alzheimer’s treatment strategyBEFORE YOU DECIDE THE RISK IS TOO HIGHThe big takeaway from this episode is that a clinical-trial ARIA percentage is not the same thing as your loved one’s individual risk.The type of ARIA matters.Whether symptoms are present matters.Genetics matter.Baseline MRI findings matter.Other medications matter.And even the way the drug is dosed may matter.That’s why this decision deserves more than a scary headline or a single percentage.In Part 1, we looked at the potential benefits of these newer anti-amyloid treatments. In this episode, we’re looking at the risks. And in Part 3, we’ll put both sides together and walk through a framework you can use to have a more informed conversation with your neurologist.If this episode helps you better understand the questions worth asking, follow or subscribe to Happy and Healthy with Amy so you don’t miss Part 3.And please share this episode with someone who is trying to make sense of an Alzheimer’s diagnosis or treatment decision.Because the more you understand what the numbers actually mean, the better prepared you’ll be to ask the questions that matter.This episode is for educational purposes only and is not medical advice. Please work with a licensed healthcare professional for diagnosis and treatment decisions.RESOURCES:Download the FREE Excerpt of Thoughts Are Habits TooPurchase Thoughts Are Habits TooBook a FREE Discovery Call with AmyDownload After Mom’s Alzheimer’s Diagnosis: The First 8 Things to Know and learn how to support her with more calm, clarity, and confidence.Download the RESTORED Protocol: Eight Essential Protective Factors to Build an Alzheimer's-Resistant BrainSchedule your Breakthrough Roadmap session with AmyFollow Amy on Instagram @amylangcoaching  and on Facebook @amylangcoachingSubscribe to Amy's YouTube channel @happyandhealthywithamy

Episode metadata supplied by the publisher feed · Published Aug 26, 2026

Embed this episode

If your mom or dad has been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s, you may be weighing whether one of the newer treatments—Leqembi or Kisunla—could be worth considering. And then you hear the words brain swelling and bleeding. For a lot of families, that’s the moment the conversation stops. But here’s the problem: those words don’t tell you the whole story. The ARIA rates reported in Alzheimer’s drug trials can sound alarming when you hear them on their ...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Understanding ARIA: How Risky Are Leqembi and Kisunla?

0:00 31:57

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Happy & Healthy with Amy?

This episode is 31 minutes long.

When was this Happy & Healthy with Amy episode published?

This episode was published on August 26, 2026.

Can I download this Happy & Healthy with Amy episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!